Growth Differentiation Factor 15 in Cardiovascular Diseases: Predicting Bleeding after Cardiac Surgery and Beyond That!

The Prognostic Potential of Growth Differentiation Factor-15 on Bleeding Events and Patient Outcome after Cardiac Surgery—A Prospective Cohort Study

Publikationsverlauf

Eingereicht: 03. Februar 2021

Angenommen: 08. Februar 2022

Accepted Manuscript online:
10. Februar 2022

Artikel online veröffentlicht:
05. Mai 2022

• References

• 1 Ceelen D, Voors AA, Tromp J. et al. Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. Eur J Heart Fail 2022; 24 (02) 308-320
• 2 Wollert KC, Kempf T, Wallentin L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 2017; 63 (01) 140-151
• 3 Negishi K, Hoshide S, Shimpo M, Kanegae H, Kario K. Growth differentiation factor-15 predicts death and stroke event in outpatients with cardiovascular risk factors: the J-HOP study. J Am Heart Assoc 2021; 10 (24) e022601
• 4 Gao Y, Bai X, Lu J. et al. Prognostic value of multiple circulating biomarkers for 2-year death in acute heart failure with preserved ejection fraction. Front Cardiovasc Med 2021; 8: 779282
• 5 Lindholm D, James SK, Gabrysch K. et al. Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes: a secondary analysis of the PLATO biomarker study. JAMA Cardiol 2018; 3 (12) 1160-1166
• 6 Mo Q, Zhuo L, Liao Z, Li R, Chen Y, Geng J. Serum GDF-15 predicts in-hospital mortality and arrhythmic risks in patients with acute myocardial infarction. Clin Appl Thromb Hemost 2022; 28: 10760 296211063875
• 7 Zelniker TA, Jarolim P, Silverman MG. et al. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS. Clin Chem Lab Med 2019; 57 (07) 1084-1092
• 8 Wang Y, Zhen C, Wang R, Wang G. Growth-differentiation factor-15 predicts adverse cardiac events in patients with acute coronary syndrome: a meta-analysis. Am J Emerg Med 2019; 37 (07) 1346-1352
• 9 Walter J, Nestelberger T, Boeddinghaus J. et al; APACE investigators. Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarction. Int J Cardiol 2019; 292: 241-245
• 10 Hagström E, James SK, Bertilsson M. et al; PLATO Investigators. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J 2016; 37 (16) 1325-1333
• 11 Lindholm D, Hagström E, James SK. et al. Growth differentiation factor 15 at 1 month after an acute coronary syndrome is associated with increased risk of major bleeding. J Am Heart Assoc 2017; 6 (04) e005580
• 12 Marín F, Roldán V. Biomarkers: GDF-15 and risk stratification in atrial fibrillation. Nat Rev Cardiol 2015; 12 (01) 8-9
• 13 Hijazi Z, Oldgren J, Lindbäck J. et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387 (10035): 2302-2311
• 14 Berg DD, Ruff CT, Jarolim P. et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation 2019; 139 (06) 760-771
• 15 Oyama K, Giugliano RP, Berg DD. et al. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2021; 42 (17) 1698-1706
• 16 Siegbahn A, Lindbäck J, Hijazi Z. et al. Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. J Thromb Haemost 2021; 19 (11) 2726-2737
• 17 Song L, Söderholm M, Svensson EH, Borné Y, Engström G. Circulating growth differentiation factor 15 levels are associated with risk of both intracerebral and subarachnoid hemorrhage. Front Neurol 2021; 12: 664010
• 18 Skowrońska M, Skrzyńska M, Machowski M. et al. Plasma growth differentiation factor 15 levels for predicting serious adverse events and bleeding in acute pulmonary embolism: a prospective observational study. Pol Arch Intern Med 2020; 130 (09) 757-765
• 19 Mulder FI, Bosch FTM, Carrier M. et al. Growth differentiation factor-15 for prediction of bleeding in cancer patients. J Thromb Haemost 2022; 20 (01) 138-144
• 20 Kazem N, Hammer A, Koller L. et al. The prognostic potential of growth differentiation factor-15 on bleeding events and patient outcome after cardiac surgery-a prospective cohort study. Thromb Haemost 2022; 122 (05) 703-714
• 21 Rossaint J, Vestweber D, Zarbock A. GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost 2013; 11 (02) 335-344
• 22 Lin JB, Sheybani A, Santeford A, De Maria A, Apte RS. Increased aqueous humor GDF15 is associated with worse visual field loss in pseudoexfoliative glaucoma patients. Transl Vis Sci Technol 2020; 9 (10) 16
• 23 Stemmler A, Symmank J, Steinmetz J, von Brandenstein K, Hennig CL, Jacobs C. GDF15 supports the inflammatory response of PdL fibroblasts stimulated by P. gingivalis LPS and concurrent compression. Int J Mol Sci 2021; 22 (24) 13608
• 24 Zang Y, Zhu Z, Xie Y. et al. Serum growth differentiation factor 15 levels are associated with depression after ischemic stroke. J Am Heart Assoc 2022; 11 (01) e022607
• 25 Wu PF, Zhang XH, Zhou P, Yin R, Zhou XT, Zhang W. Growth differentiation factor 15 is associated with Alzheimer's disease risk. Front Genet 2021; 12: 700371
• 26 Srour B, Kaaks R, Johnson T, Hynes LC, Kühn T, Katzke VA. Ageing-related markers and risks of cancer and cardiovascular disease: a prospective study in the EPIC-Heidelberg cohort. Eur J Epidemiol 2022; 37 (01) 49-65
• 27 Jovani M, Liu EE, Paniagua SM. et al. Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?. Cardiovasc Res 2021;
• 28 Alserawan L, Peñacoba P, Orozco Echevarría SE. et al. Growth differentiation factor 15 (GDF-15): a novel biomarker associated with poorer respiratory function in COVID-19. Diagnostics (Basel) 2021; 11 (11) 1998
• 29 Teng X, Zhang J, Shi Y. et al. Comprehensive profiling of inflammatory factors revealed that growth differentiation factor-15 is an indicator of disease severity in COVID-19 patients. Front Immunol 2021; 12: 662465
• 30 Myhre PL, Prebensen C, Strand H. et al. Growth differentiation factor 15 provides prognostic information superior to established cardiovascular and inflammatory biomarkers in unselected patients hospitalized with COVID-19. Circulation 2020; 142 (22) 2128-2137
• 31 Camelo-Castillo A, Rivera-Caravaca JM, Marín F, Vicente V, Lip GYH, Roldán V. Predicting adverse events beyond stroke and bleeding with the ABC-Stroke and ABC-Bleeding Scores in patients with atrial fibrillation: the Murcia AF project. Thromb Haemost 2020; 120 (08) 1200-1207
• 32 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
• 33 Lip GYH, Banerjee A, Boriani G. et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018; 154 (05) 1121-1201
• 34 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
• 35 de Vries TAC, Hirsh J, Xu K. et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?-a systematic review. Thromb Haemost 2020; 120 (09) 1323-1329